Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Vaccine Candidate in Adults 60 Years and Older
NCT06251024Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Primary endpoint: First episode of RSV-LRTD (RSV A and/or RSV B). Started Apr 2024; status: completed.
02
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06251024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251024.